 |
市場調査レポート
商品コード
1448374
セルベースアッセイの世界市場規模、シェア、成長分析：製品・サービス別、用途別、最終用途別 - 産業予測（2024～2031年）Global Cell-Based Assays Market Size, Share, Growth Analysis, By Products & Services, By Application, By End-Use - Industry Forecast 2024-2031 |
||||||
| セルベースアッセイの世界市場規模、シェア、成長分析：製品・サービス別、用途別、最終用途別 - 産業予測（2024～2031年） |
|
出版日: 2024年03月04日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のセルベースアッセイの市場規模は、2022年に176億米ドルとなり、2023年の191億4,000万米ドルから、2031年までには374億4,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは8.75％で成長する見通しです。
主要な臨床試験や創薬への取り組みを含む世界の研究の状況は、COVID-19の大流行の中で大きな混乱に見舞われました。研究の滞りに対応するため、世界中の研究者が効率的で時間的制約の少ない手法を迅速に導入しました。COVID-19感染を検出するために調整された数多くのセルベースアッセイが開発され、そのいくつかは世界の緊急用としてFDAの承認を得ました。その一例が、Adaptive BiotechnologiesによるT-Detect COVID-19ルーチンT細胞検査で、2021年5月に米国FDAから緊急使用認可を取得しました。この革新的な次世代シーケンス（NGS）ベースの検査は、SARS-CoV-2抗原を認識するT細胞の同定を容易にし、最近の感染を確認します。
セルベースの薬剤スクリーニングアッセイは創薬研究に不可欠であり、膨大な化合物ライブラリーから有望な薬剤候補を慎重に選択することを容易にしています。これらのアッセイは、様々な医薬品開発の軌跡における多面的な考慮事項の影響を受け、多様なスペクトルをカバーしています。Fraunhofer Instituteの研究者が2022年9月に発表した画期的な開発品Proxidrugsのような、創薬研究において期待される進歩は、感染症、がん、アルツハイマー病のような病態に対処するために廃棄物処理システムを活用し、科学的革新と治療法の進化を推進するセルベースアッセイの汎用性を強調しています。
市場は現在、創薬需要の高まり、バイオテクノロジー研究のニーズの増加、感染症、がん、自己免疫疾患、遺伝子異常の発生率の増加などの要因により、力強い成長を遂げようとしています。セルベースアッセイは、創薬プロセスにおいて、潜在的な薬剤候補の検証だけでなく、リード化合物のプロファイリング、細胞シグナル伝達の分析、毒性の評価など、極めて重要な役割を果たしています。その一例が、Cell BiologicsのAnnexin V-Cy3アポトーシス検出キットで、蛍光を利用してアポトーシスを検出します。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
セルベースアッセイの世界市場：製品・サービス別
- 市場概要
- 試薬
- アッセイキット
- 細胞増殖アッセイ
- レポーター遺伝子アッセイ
- 細胞死アッセイ
- セカンドメッセンジャーアッセイ
- マイクロプレート
- プローブ・ラベル
- 機器・ソフトウェア
- 細胞株
- 初代細胞株
- 幹細胞株
- 不死化細胞株
セルベースアッセイの世界市場：用途別
- 市場概要
- 基礎調査
- 創薬
- その他の用途
セルベースアッセイの世界市場：最終用途別
- 市場概要
- 製薬会社・バイオテクノロジー会社
- 学術調査機関
- 受託調査機関
セルベースアッセイの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Thermo Fisher Scientific, Inc.（United States）
- Promega Corporation（United States）
- Merck KGaA（Germany）
- PerkinElmer, Inc.（United States）
- Danaher Corporation（United States）
- Cell Signaling Technology, Inc.（United States）
- Bio-Rad Laboratories, Inc.（United States）
- Agilent Technologies, Inc.（United States）
- GE Healthcare（United Kingdom）
- Lonza Group Ltd.（Switzerland）
Global Cell-Based Assays Market size was valued at USD 17.6 billion in 2022 and is poised to grow from USD 19.14 billion in 2023 to USD 37.44 billion by 2031, growing at a CAGR of 8.75% during the forecast period (2024-2031).
The global landscape of research, encompassing major clinical trials and endeavors in drug discovery, underwent significant disruptions amid the COVID-19 pandemic. In response to research backlogs, researchers globally swiftly embraced efficient and time-sensitive methodologies. Numerous cell-based assays tailored for detecting COVID-19 infections were developed, with several gaining FDA approval for global emergency use. An illustrative instance is the T-Detect COVID-19 routine T-cell test by Adaptive Biotechnologies, obtaining Emergency Use Authorization from the U.S. FDA in May 2021. This innovative Next-Generation Sequencing (NGS)-based test facilitates the identification of T-cells recognizing SARS-CoV-2 antigens, confirming recent infections.
Cell-based drug screening assays have been integral in drug discovery research, facilitating the careful selection of promising drug candidates from extensive compound libraries. These assays cover a diverse spectrum, influenced by multifaceted considerations in various drug development trajectories. Anticipated advancements in drug discovery, such as the groundbreaking development unveiled in September 2022 by Fraunhofer Institute researchers-Proxidrugs-highlight the versatility of cell-based assays in driving scientific innovation and therapeutic evolution, harnessing waste disposal systems to address conditions like infections, cancer, and Alzheimer's disease.
The market is currently poised for robust growth due to factors like a rising demand for drug discovery, an increased need for biotechnology research, and the growing incidence of infectious diseases, cancer, autoimmune disorders, and genetic anomalies. Cell-based assays play a pivotal role in the drug discovery process, not only for validating potential drug candidates but also for lead profiling, analyzing cellular signaling, and assessing toxicity. An exemplary illustration is The Annexin V-Cy3 apoptosis detection kit by Cell Biologics, utilizing fluorescence to detect apoptosis-a testament to the diverse applications of these assays in comprehensive cellular analysis.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell-Based Assays Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cell-Based Assays Market Segmental Analysis
The global cell-based assays market is segmented on the basis of product & services, application, end - use, region. By product & services, the market is segmented into reagents, assay kits, cell growth assays, reporter gene assays, cell death assays, second messenger assays, microplates, probes & labels, instruments & software, cell lines, primary cell lines, stem cell lines, immortalized cell lines. By application, the market is segmented into basic research, drug discovery, other applications. By end - use, the market is segmented into pharmaceutical and biotechnology companies, academic & research institutes, contract research organizations. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.
Drivers of the Global Cell-Based Assays Market
The rising incidence of chronic conditions like cancer, cardiovascular diseases, and neurodegenerative disorders is driving the need for sophisticated cell-based assays in disease modeling and drug testing.
Restraints in the Global Cell-Based Assays Market
Creating and executing cell-based assays can be demanding in terms of resources, as expenses related to reagents, equipment, and proficient personnel can present obstacles, especially for smaller research organizations.
Market Trends of the Global Cell-Based Assays Market
The trend towards utilizing 3D cell culture models that closely mimic physiological conditions is increasingly gaining momentum. This shift facilitates a more accurate replication of in vivo environments, thereby enhancing the efficacy of drug screening and toxicity assessment processes.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Cell-Based Assays Market by Products & Services
- Market Overview
- Reagents
- Assay Kits
- Cell Growth Assays
- Reporter Gene Assays
- Cell Death Assays
- Second Messenger Assays
- Microplates
- Probes & Labels
- Instruments & Software
- Cell Lines
- Primary Cell Lines
- Stem Cell Lines
- Immortalized Cell Lines
Global Cell-Based Assays Market by Application
- Market Overview
- Basic Research
- Drug Discovery
- Other Applications
Global Cell-Based Assays Market by End-Use
- Market Overview
- Pharmaceutical and Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations
Global Cell-Based Assays Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Thermo Fisher Scientific, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Promega Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cell Signaling Technology, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GE Healthcare (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza Group Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
